Citations

Clear

3042 citation(s) found for "Kumar, S".

Significant in-Vitro Activity of a Novel JAK2 Inhibitor in Multiple Myeloma Associated with Preferential Cytotoxicity for CD45+ Myeloma Cells.
Haug, Jessica, Kimlinger, Teresa K. , Halling, Timothy, Wellik, Linda, Pardanani, Animesh , Tefferi, Ayalew , Kumar, Shaji , Ramakrishnan, Vijay , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 11, 2019 | Volume: 114 | Issue: 22 | Pages: 2848-2848

10.1182/blood.v114.22.2848.2848 Get It

Abstract Abstract 2848 Poster Board II-824 Background: Multiple myeloma remains incurable with current therapies and novel approaches based on disease biology are needed. IL-6 is a critical cytokine involved in myeloma cell proliferation and survival and exerts its activity primarily through the JAK/STAT pathway. In addition to IL6, other cytokines are also believed to cross talk with the JAK/STAT pathway, making it a crucial interface for survival signals. It has been implicated in myeloma cell interaction with the microenvironment and resistance to apoptotic stimuli from different drugs, and represents a potential therapeutic target. We examined the pre-clinical activity of a novel JAK2 tyrosine kinase inhibitor TG101209. Methods: TG101209 (N-tert-butyl-3-(5-methyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ylamino)-benzenesulfonamide) was synthesized by TargeGen Inc. (San Diego, CA, USA). Stock solutions were made in DMSO, and subsequently diluted in RPMI-1640 medium for use. MM cell lines were cultured in RPMI 1640 containing 10% fetal bovine serum (20% serum for primary patient cells) supplemented with L-Glutamine, penicillin, and streptomycin. Cytotoxicity was measured using the MTT viability assay and proliferation using thymidine uptake. Apoptosis was measured using flow cytometry upon cell staining with Annexin V-FITC and propidium iodide (PI) for cell lines and using Apo2.7 in primary patient cells. CD45 expression was estimated using flow cytometry and cells were gated by their CD45 expression to assess differential effects of the drug. Immunoblotting was done on cell extracts at various time points following incubation with the drug in order to study the cell signaling pathways. Results: TG101209 resulted in a dose and time dependent inhibition of cell growth in the MM cell lines tested. Most of the cytotoxicity was evident by 48 hours, with minimal increase seen up to 96 hours of incubation. At 48 hours of incubation, the median inhibitory concentration was between 2 and 4uM with similar IC50 seen for myeloma cell lines sensitive or resistant to conventional therapies. The IC50s were maintained when the cells were treated in co-culture with stromal cells or in the presence of IL6, IGF or VEGF. Increasing doses of IL6 was not able to rescue the cells from the drug. Dose dependent decrease in proliferation of the cell lines was evidenced by decreased thymidine incorporation. Apoptotic changes in cells following drug treatment was confirmed by flow cytometry for Annexin and PI. Cleavage of caspases 3, 8 and 9 were confirmed on flow cytometry. Addition of the pan-caspase inhibitor zvad-fmk did not prevent drug-induced apoptosis confirming non-caspase mediated mechanisms of cell death as well. Primary myeloma cells from several patients were treated with increasing doses of the drug and IC50 similar to cell lines were seen in 8/10 patient samples tested. Interestingly, evaluation of U266 cell lines, which have a mix of CD45+ and negative cells as well as primary patient cells demonstrated more profound cytotoxicity and anti-proliferative activity of the drug on the CD45+ population relative to the CD45- cells. Immunoblotting studies demonstrated significant down regulation of IL-6 induced pSTAT3 with minor effects on the pERK and pAkt. The effect on pSAT3 was sustained compared to that on pERK and pAkt. This was accompanied by significant down regulation of Bcl-xL. Studies in a mouse model of myeloma are planned. Conclusion: These studies demonstrate significant in-vitro activity of JAK2 inhibition in multiple myeloma. In particular, the preferential targeting of CD45 cells, considered to reflect the proliferative compartment in myeloma holds out the promise for more sustained impact on the disease from a therapeutic standpoint. This is likely explained by the increased sensitivity of the CD45 cells to cytokines as a result of higher expression of different cytokine receptors as has been previously shown. This leads to increased activity of and dependence of the cells on the JAK-STAT pathway and likely explains the increased effect of the pathway inhibition. These studies form the framework for clinical evaluation of the drug in the setting of myeloma. Disclosures: Kumar: CELGENE: Research Funding; MILLENNIUM: Research Funding; BAYER: Research Funding; GENZYME: Research Funding; NOVARTIS: Research Funding.
Infectious Complications in Advanced Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide (Revlimid +/- Corticosteroids).
Kukreti, Vishal , Dean, Saima, Kumar, Deepali , Trudel, Suzanne , Reece, Donna , Chen, Christine , Masih‐Khan, Esther , Mıkhael, Joseph

Mayo Clinic

Blood | October 11, 2019 | Volume: 114 | Issue: 22 | Pages: 2876-2876

10.1182/blood.v114.22.2876.2876 Get It

Abstract Abstract 2876 Poster Board II-852 Multiple myeloma (MM) patients (pts) are immunosuppressed given the underlying disease, previous treatments and myelosuppression seen on lenalidomide (Revlimid, Rev). We evaluated the infectious complications seen on Celgene's Expanded Access Rev program at Princess Margaret Hospital. We have treated 75 pts who had progressed after at least one prior therapy as part of a national study in Canada. At entry, pts were required to have a neutrophil count of ≥1.0 ×109/L. The median age was 61 yrs (range 35-79); 52% were males. Prior therapy included stem cell transplant in 65, thalidomide in 54 and bortezomib in 24. Number of lines of prior therapy were as follows: 24 (one), 29 (two), 16 (three), 8 (four) and one (five). Neupogen was used liberally (63%) after a patient had a dose delay on trial due to neutropenia. Patients were treated with full dose lenalidomide at entry onto clinical trial and were maintained on full dosing unless platelet counts were <30×109/L or ANC was <1.0×109/L. No other dose adjustments were made for renal dysfunction. Results: There were 32 pts (43%) who had a clinically evident infection; the majority (91%) was on prophylactic antibiotics (septra/ciprofloxacin) at the time. There were two deaths due to infection and 23 pts (72%) required hospitalization (range 2-27 days). The majority of infections occurred within the first 4 cycles of treatment (26 pts) and seemed to occur more in pts with several lines of prior therapy – 7/24 (29%) with 1 prior therapy, 14/29 (48%) with 2, 9/16 (56%) with 3 and 2/8 (25%) with 4 prior therapies. Sixteen were neutropenic of which 7 had febrile neutropenia (9%). The types of infections were: respiratory in 14 (1 with pneumocystis pneumonia), cellulitis in 4, herpes simplex and herpes zoster in 2 pts each. These included streptococcus pneumoniae (1), staphylococcus aureus (3), respiratory syncitial virus (1) and mycobacterium chelonae (1). Rev was held during the infection in 23 pts (72%). Conclusions: 1) Infections are frequent in this patient population (43%) and often lead to hospitalization (72%); respiratory infections accounted for a large majority (43%). 2) Early aggressive growth factor support and broader antibiotic prophylaxis may be of benefit especially in heavily pretreated patients. 3) Dose reduction of Rev in the context of serious infections should be further evaluated. Disclosures: Kukreti: Celgene: Honoraria. Trudel:Celgene: Honoraria, Speakers Bureau; Ortho Biotech: Honoraria. Chen:Celgene: Honoraria.
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.
Jayabalan, David , Kumar, Shaji , Pearse, Roger, Leonard, John P. , Lacy, Martha Q. , Coleman, Morton , Hayman, Suzanne R. , Lust, John A., Kyle, Robert A. , Greipp, Philip R., Stewart, A. Keith, Niesvizky, Rubén, Gay, Francesca , Rajkumar, S. Vincent , Mark, Tomer M , Dispenzieri, Angela , Gertz, Morie A. , Chen‐Kiang, Selina , Roy, Vivek , Buadi, Francis K. , Witzig, Thomas E. , Fonseca, Rafaël

Mayo Clinic

Blood | October 11, 2019 | Volume: 114 | Issue: 22 | Pages: 2868-2868

10.1182/blood.v114.22.2868.2868 Get It

Abstract Abstract 2868 Poster Board II-844 Background and Objective: In newly diagnosed multiple myeloma (MM), the combination of lenalidomide plus high-dose dexamethasone (RD) is superior to high-dose dexamethasone (Zonder JA et al, Blood 2007;110:77). Preliminary results show that lenalidomide plus low-dose dexamethasone (Rd) has better 2-year overall survival (OS) compared with RD (Rajkumar SV et al, J Clin Oncol 2008;26:8504). The addition of clarithromycin (Biaxin) to lenalidomide and low-dose dexamethasone (BiRd) has been investigated in a phase II study, demonstrating a high response rate and 2-year OS (Niesvizky R at al, Blood 2008;111:1101-1109). However, the additive value of clarithromycin is not known. No randomized trials have compared Rd versus BiRd, none are planned. The objective of this case–matched study was to compare the efficacy and the toxicity of BiRd vs Rd as initial therapy for newly diagnosed MM. Patients and methods: Data from 72 newly diagnosed MM patients treated at the New York Presbyterian Hospital–Cornell Medical Center, from December 2004 to December 2006, with BiRD, were analyzed. For comparison, an equal number of pair mates were selected among newly diagnosed patients seen at the Mayo Clinic who received Rd, from March 2005 to December 2008. Case matching was performed with respect to age, gender, and transplant status. Patients treated with BiRd received oral lenalidomide (25 mg/day, days 3-21 of cycle 1; days 1-21 of subsequent cycles); dexamethasone (40 mg days 1, 2, 3, 8, 15, 22 of cycle 1; days 1, 8, 15, and 22 of each subsequent cycle); clarithromycin (500 mg twice daily, from day 2 of cycle 1). Patients treated with Rd received oral lenalidomide (25 mg/day, days 1-21) plus low-dose dexamethasone (40 mg days 1, 8, 15, 22). In both groups patients were allowed to discontinue treatment to pursue transplant, but treatment until progression, relapse or unacceptable toxicity was permitted at the physician's discretion. Outcome was analyzed on an intention-to-treat basis. The Chi-square or the rank sum tests were used to compare variables. Time-to-event analysis was performed using the Kaplan-Meier method; comparisons were determined by the log-rank test and the Cox proportional hazards model. Results: Median duration of treatment was 11.8 months in the BiRd group vs 6 months in the Rd group. On intention-to-treat analysis, complete response was significantly higher with BiRd compared to Rd (45.8% vs 13.9%, respectively, p<0.001); similarly very good partial response (VGPR) or better was higher with BiRd (73.6% vs 33.3%, p<0.001). Rates of VGPR or better, after 6 months and 1 year of therapy, were significantly higher in BiRd patients. Both time-to-progression (TTP) (median 48.3 months vs 27.5 months; HR 0.51; 95% CI 0.25-1.06; p=0.071) and PFS (median 48.3 months vs 27.5 months, HR 0.50; 95% CI 0.25-0.98; p=0.044) were higher with BiRd. Median time to next treatment (TTNT) was not reached in BiRd group compared to 29.9 months in Rd patients (HR 0.37 95% CI 0.20-0.66, p<0.001). There was a trend toward better OS with BiRd, (3-year OS: 89.7% vs 73.0%), but the difference was not statistically significant (HR 0.48; 95% CI 0.17-1.37; p=0.170). Thirty-two patients in each group received transplant; median time to transplant was longer in BiRd group (13.5 vs 5.9 months). Results of survival, for patients who received transplant and patients who did not, were similar to those of the total population. On subset analysis, among patients presenting with International Staging System (ISS) stage I/II at diagnosis, TTP, PFS and TTNT were significantly longer in BiRd patients; no significant differences were found among patients with ISS stage III. Main grade 3-4 toxicities of BiRd were hematological, in particular thrombocytopenia (23.6% vs 8.3%, p=0.012); rate of neutropenia was similar between the 2 groups (19.4% vs 16.7%, p=0.665). Infections (16.7% vs 9.7%, p=0.218) and dermatological toxicity (12.5% vs 4.2%, p=0.129) were higher in patients who received Rd. Rate of venous thromboembolism was similar in the 2 groups (9.7% vs 12.5%, respectively in Rd and BiRd patients, p=0.596). Conclusion: Results of this case-control analysis suggest superiority of BiRd in terms of response rate and survival, compared with Rd, and suggest that there may be a significant additive value when clarithromycin is added to Rd. These data indicate the need for randomized prospective phase III studies to evaluate BiRd versus Rd in the treatment of MM. Disclosures: Off Label Use: research drug in combination to standard of care. Kumar:celgene: Research Funding; millenium: Research Funding; bayer: Research Funding; novartis: Research Funding; genzyme: Research Funding. Mark:celgene: Research Funding. Dispenzieri:celgene: Research Funding. Gertz:celgene: Honoraria; genzime: Honoraria; millenium: Honoraria; amgen: Honoraria. Leonard:celgene: Consultancy. Lacy:celgene: Research Funding. Witzig:celgene: Research Funding. Fonseca:medtronic: Consultancy; genzyme: Consultancy; celgene: Consultancy; amgen: Consultancy; BMS: Consultancy; otsuka: Consultancy. Greipp:celgene: Research Funding. Niesvizky:celgene: Research Funding, Speakers Bureau; Millenium: Research Funding, Speakers Bureau; Proteolix: Research Funding, data monitoring committee.
Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM)
Quill, Timothy A., Kumar, Shaji , Lentzsch, Suzanne , Roodman, G. David, Brady, Erik D., Mortimer, Jim, Obholz, Kevin L, Lonial, Sagar , Anderson, Kenneth C.

Mayo Clinic

Blood | October 11, 2019 | Volume: 126 | Issue: 23 | Pages: 2105-2105

10.1182/blood.v126.23.2105.2105 Get It

Abstract Background Clinical practice guidelines for MM list many alternative therapeutic options with an equivalent category of evidence but lack recommendations on the best approaches for individual patient cases. To provide clinicians with expert guidance on treatment options for defined patient scenarios, we developed and updated an interactive, online decision aid that allows users to enter specific disease and patient characteristics, enter their planned treatment, and then compare their choice of therapy with those of an MM expert panel for that scenario. Here we report data from the most recent version (2015) of this tool, capturing changes in expert recommendations and treatment trends for MM over time and evaluating the impact of this online tool on clinical care. Methods Each of 3 annual updates to the tool were developed with input from a panel of 5 MM experts. The individual experts provided treatment recommendations for multiple patient scenarios across the settings of induction therapy, maintenance therapy, and therapy for relapsed/refractory MM. A series of pull-down menus allowed users to select individual patient and disease characteristics identified by experts as important to consider when making treatment choices. These characteristics included: eligibility for autologous stem cell transplantation (for induction therapy only), results of chromosome analysis (cytogenetics/FISH), ECOG performance status, risk of renal insufficiency or peripheral neuropathy, previous therapy and depth of response (for maintenance and relapsed/refractory settings), and cardiac or pulmonary dysfunction (for relapsed/refractory setting). Users were then asked to state their intended management approach for that particular patient scenario. Once completed, recommendations for that scenario from each of the experts were displayed, and users were asked to indicate the impact of the expert recommendations on their treatment choice. Results Expert recommendations spanning the continuum of care were compiled in October 2012, November 2013, and March 2015 for the 3 different MM tool updates. As for earlier versions of the MM tool, each of the experts in the 2015 update provided recommendations for 32 case scenarios for induction therapy, for a total of 160 possible induction recommendations. Comparing overall induction therapy recommendations the use of bortezomib/lenalidomide/dexamethasone was approximately 40% in both 2013 and 2015, whereas the use of carfilzomib-containing regimens increased from 5% to 17%. None of the experts chose regimens with melphalan as induction therapy in 2015. In the relapsed/refractory setting, the use of newer therapeutic approaches continued to grow especially in the setting of patients who did not respond to induction therapy or relapsed within 6 months. For example, in those with prior proteasome inhibitor (PI) therapy, the selection of carfilzomib/lenalidomide/dexamethasone by experts rose from 11% to 38% from 2013 to 2015 with pomalidomide and lenalidomide selected for 20% to 25% of cases in the most recent tool. For prior IMiD and PI, the experts selected a new combination of pomalidomide with a PI (either bortezomib or carfilzomib) and dexamethasone in 55% of the case scenarios in 2015. To date, 170 different clinicians sought guidance on more than 259 patient case scenarios using the 2015 decision support tool. In the subset of cases (n = 104) in which users reported how the tool affected their management of patients with MM, 68% indicated the expert recommendations either confirmed or changed their intended treatment (22% changed; 46% confirmed), whereas 17% indicated that there would be barriers to implementing the expert recommendations, and 5% said they disagreed with the experts' recommendations. Conclusions Expert opinions regarding optimal MM therapy continue to evolve with new evidence. Our data show that interactive online therapy decision aids that provide expert recommendations to clinicians for specific case scenarios can aid decision making and capture practice trends in this rapidly evolving environment. Preliminary data suggest that most clinicians using the online decision aid either confirmed or changed their treatment approaches for specific MM patient case scenarios based on expert recommendations. A detailed and updated analysis of expert and user data will be presented. Disclosures Kumar: Janssen: Consultancy, Research Funding; Novartis: Research Funding; Onyx: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Skyline: Consultancy, Honoraria; BMS: Consultancy; Sanofi: Consultancy, Research Funding. Lentzsch:BMS: Consultancy; Novartis: Consultancy; Axiom: Honoraria; Janssen: Consultancy; Celgene: Consultancy. Lonial:Novartis: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Onyx: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Celgene: Consultancy, Research Funding. Roodman:Amgen: Consultancy; Eli Lilly: Research Funding. Mortimer:AstraZeneca: Other: spouse is an employee of and has equity ownership in.
Sequential Heart and Autologous Stem Cell Transplantation for AL Amyloidosis.
Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Kyle, Robert A. , Edwards, Brooks S., Rodeheffer, Richard J. , Robert, Frantz P., Kushwaha, Sudhir S. , Clavell, Alfedo L., Sundt, Thoralf M. , Daly, Richard C. , McGregor, Christopher G.A. , Gastineau, Dennis A. , Dispenzieri, Angela , Rajkumar, S. Vincent , Dearani, Joseph A. , Gertz, Morie A.

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3092-3092

10.1182/blood.v108.11.3092.3092 Get It

Abstract Background: Patients with AL and congestive heart failure have a median survival of less than one year. Methods: Between 1994 and 2005, 11 patients underwent sequential heart transplant followed by autologous peripheral blood stem cell transplant (SCT) for treatment of AL. Patients had heart dominant AL with minimal/no other organ impairment and no evidence of multiple myeloma. Results: Patients ranged in age from 35 to 63 years (median 54). All had biopsy proven amyloidosis and monoclonal protein detectable in serum (73%) or urine (100%). Free light chain assay was available prior to SCT in 6 and was abnormal in all. All patients presented with NYHA Class III or IV heart failure. All but two patients had no other organ involved at the time of heart transplant. One patient had his heart transplant at another facility and had renal involvement at the time of heart transplant. One patient had peripheral nerve involvement documented prior to heart transplant. Five patients had progression of amyloid to involve other organs by the time of SCT. These included: renal (6), peripheral nerve (2), macroglossia (3), gastrointestinal (2). The median time from diagnosis to heart transplant was 3 months (range 1 to 5). The median time from heart transplant to SCT was 8 months, (range 3 to 24). Conditioning chemotherapy consisted of melphalan 200 mg /m2 (6 patients) or melphalan 140 mg/m2 (5 patients). Two patients died of complications before day +100, (TRM of 18%). Hematologic remissions were seen in 8 and organ responses in 3. Five were unable to be evaluated for organ response due to the heart transplant. Three died from progressive amyloidosis at 66, 56.7, and 55 months following SCT. The median survival is 56.7 months from SCT. Six are alive with a median follow-up of 24 months, range 9 to 90 months. Among the 6 surviving patients, one patient relapsed and one patient has failed to improve, but 4 patients are in continued remission. One patient developed secondary myelodysplastic syndrome. Conclusions: Heart transplant followed by SCT is feasible and offers durable remissions for carefully selected patients with cardiac AL. Figure Figure
Autologous Stem Cell Transplantation Provides Additional Cytoreduction Following Induction Therapy in Multiple Myeloma.
Kumar, Shaji , Lacy, Martha Q. , Hayman, Suzanne R. , Zeldenrust, Steven R., Lust, John A., Greipp, Philip R., Kyle, Robert A. , Dispenzieri, Angela , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3099-3099

10.1182/blood.v108.11.3099.3099 Get It

Abstract Background: High dose therapy (HDT) and stem cell transplant has been shown to improve survival in patients with myeloma and remains the standard of care. However, the reported results of initial HDT in these patients reflect the combined effect of the initial therapy and the HDT. The contribution of HDT on its own is often difficult to analyze in this group of patients with varying degree of response to initial therapy. In this single institution retrospective study, we have analyzed the results of HDT in a group of patients with measurable disease at the time of HDT. Methods: We identified patients from our transplant database, who had measurable disease at the time of initiation of transplant as defined by a serum M protein of ≥ 1.0 g/dL, 24 hour urine M-protein ≥ 200 mg or a bone marrow plasma cell % of ≥ 30. Details regarding the clinical outcome were obtained from the database and from patient clinical records. Chi square test was used for comparison of nominal variables and t-test for continuous variables. Kaplan Meier analysis was used for comparing survival and Cox proportional hazards was employed to identify predictors of progression free and overall survival. Responses were defined by the EBMTR criteria, using the measurements at the time HDT and the lowest measurement obtained. VGPR required a 90% reduction in the serum M component with urine protein &lt; 100 mg/24 hours. Results: A total of 440 patients were studied; 271 (61.5%) of whom had a transplant within one year of their diagnosis. Among the 271 patients, 140 (52%) were in the initial plateau, 99 (36%) failed to achieve a PR to initial therapy and 32 (12%) were in their first relapse. Given the known differences in the outcome between these groups of patients, those receiving an early transplant were analyzed separately. The response rates included CR (24%), VGPR (7%), PR (52%), MR or less (17%) and among the late transplants CR (23%), VGPR (8%), PR (61%) and MR or less (8%). The median progression free survival was 23.6 mos and the overall survival from HDT was 62 mos. In a multivariate analysis, presence of cytogenetic abnormalities (RR: 2.5) and high plasma cell labeling index (≥ 1%) (RR: 2.4) at HDT and failure to achieve a CR or VGPR (RR: 1.7) were prognostic for decreased progression free survival post HDT. In a similar model, only high PCLI (RR: 2.8) and abnormal cytogenetics (RR: 2.5) at HDT predicted for poor overall survival after transplant. Conclusion: This study provides a sense of the contribution of HDT, independent of the initial therapy, by determining responses based on the immediate pre-transplant disease measurements and the best values observed post transplant. In this group of patients with residual measurable disease after the initial therapy, HDT therapy leads to complete responses in nearly a quarter of the patients and a VGPR in another 7%, an outcome associated with better progressin free survival. While measurements at transplant do not correlate strictly with response to initial therapy, the aim of this study was to understand the individual contribution of HDT in these patients. Thus some of the patients who would have been classified as having a partial response to induction and HDT may be classified as non-responders in this analysis. These numbers will provide a historical comparison for trials evaluating novel consolidation therapies for myeloma.
Epigallocatechin-3-Gallate (EGCG), a Polyphenol Extracted from Green Tea, Has Significant In Vitro Activity Against Myeloma Cells.
Kumar, Shaji , Timm, Michael, Haug, Jessica, Kimlinger, Teresa K. , Wellik, Linda, Kline, Michael, Rajkumar, S. Vincent

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3465-3465

10.1182/blood.v108.11.3465.3465 Get It

Abstract Background: Epigallocatechin-3-gallate (EGCG) is a polyphenol extracted from green tea that has been studied for cancer prevention and treatment. Green tea and its extracts have been an integral part of traditional medicines from Asia and are thought to have considerable medicinal value. EGCG has been studied in many tumor types and in vitro studies have been encouraging. It is currently in Phase I/II clinical trial in the treatment of chronic lymphocytic leukemia. Here we examined the activity of EGCG in the setting of myeloma and its potential mechanisms of action. Methods: MM cell lines were cultured in RPMI 1640 containing 10% fetal bovine serum supplemented with L-Glutamine, penicillin, and streptomycin. The KAS-6/1 cell line was also supplemented with 1 ng/ml IL-6. Cytotoxicity of EGCG was measured using the MTT viability assay. Apoptosis was measured using flow cytometry upon cell staining with Annexin V-FITC and propidium iodide (PI). Fresh myeloma cells were obtained from bone marrow aspirates and subjected to ACK lysis to remove red cells. These cells were cultured in RPMI1640 with or with out EGCG and apoptotic rates were determined by Apo 2.7 expression on gated plasma cells. Flow cytometry was used for determining the phosphorylation state of various signaling proteins. Anti-angiogenic activity of EGCG was measured using a human in vitro angiogenesis kit (Angiokit). Results: EGCG treatment of myeloma cell lines resulted in dose- and time-dependent cytotoxicity to the cells. EGCG was cytotoxic to several myeloma cell lines, including IL-6 dependent cell lines KAS-6/1 and ANBL-6 as well as drug resistant cell lines MM1.R, Dox40 and LR5. The effect was maintained when the cells were grown in co-culture with marrow stromal cells, indicating the ability to overcome microenvironment mediated resistance. EGCG induced apoptosis of myeloma cell lines, apoptotic cells being measured as Annexin (+)/PI (−) cells by flow cytometry. It induced a dose-dependent apoptosis of freshly isolated myeloma cells with increased effect seen on the CD45+ myeloma cells compared to CD45- cells, reflecting increased activity on the proliferative fraction. Down regulation of Akt phosphorylation was seen following treatment of myeloma cells with EGCG. Using the Angiokit, we were able to demonstrate inhibition of tubule formation by EGCG at concentrations lower than those cytotoxic to myeloma cells. It was also able to overcome the angiogenic activity of VEGF. Conclusion: We demonstrate potent anti-myeloma activity of EGCG in vitro. In vivo studies in animal models of myeloma are ongoing. We demonstrate, as in other cell lines, inhibition of Akt pathways as a potential mechanism of action of EGCG. Ongoing studies are exploring other mechanisms. Most importantly, we demonstrate anti-angiogenic activity of this compound in the setting of myeloma, a finding in concordance with the inhibition of VEGF activity seen with other tumor systems.
Apoptosis Rates in Myeloma Cells Can Be Significantly Affected by CD138 Sorting and by the Specific Method Used To Detect Apoptotic Cells.
Kimlinger, Teresa K. , Kline, Michael, Timm, Michael, Haug, Jessica, Kumar, Shaji , Rajkumar, S. Vincent , Witzig, Thomas E.

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3442-3442

10.1182/blood.v108.11.3442.3442 Get It

Abstract Background: The clonal plasma cells in multiple myeloma have relatively low rates of apoptosis. We have previously shown that the apoptotic rates of the plasma cells have prognostic value in these patients. However, several methods are used both for targeting the myeloma cells for study as well as for detection of apoptosis in these cells. It is not clear which method is optimal for studying apoptotic rates of plasma cells from primary patient samples. We examined two different ways of studying the plasma cells, namely CD138 magnetic bead based positive selection of myeloma cells (sorted) and gating on the plasma cells in whole bone marrow (unsorted) using CD38/CD45 expression patterns. Additionally, we compared two different methods of identifying apoptotic plasma cells. Methods: Paired samples processed by two different methods were studied. The bone marrow aspirate samples were initially processed using ACK lysis to remove the red cells. The samples were then studied using flow cytometry (unsorted sample) or subjected to a second step of magnetic bead based separation of myeloma cells based on CD138 expression (sorted sample). Each of the samples was studied using Annexin/PI and Apo 2.7 expression to identify the plasma cells undergoing apoptosis. Plasma cells were identified in the unsorted samples by virtue of their CD38/CD45 expression. Samples were studied at collection and after 48 hours of culture. Results: At collection, the median percentages of cells considered apoptotic by annexin/PI (Annexin pos, PI neg) were higher than that detected by the Apo 2.7 method (Apo 2.7 + cells), for both sorted (6.5% vs. 1.5%) and unsorted cells (26% vs. 10%). However, after 48 hours of culture the percentage of apoptotic cells detected using the Apo 2.7 method were higher than that by Annexin/PI for both sorted (22.5% vs. 14.5%) and unsorted cells (43.5% vs. 10%). When the 48 hr study was compared with the initial study, percent apoptotic cells detected by Apo 2.7 had increased at 48 hrs for both sorted and unsorted cells. However, the percentage of apoptotic cells by annexin/PI had decreased in the unsorted cells at 48 hrs compared to initial study. The sorted samples had an overall increase in apoptosis at 48 hours as measured by annexin/PI. We then looked at the percentage of apoptotic cells detected by either method on initial study and compared the sorted cells and unsorted cells. Using either method, the percentage of apoptotic cells was significantly less (P=0.01; paired t-test) among the sorted cells compared to the unsorted cells. Conclusion: Previous studies have shown that CD138 expression is lost from PCs as they enter apoptosis. Here we show in paired samples that the percentage of apoptotic myeloma cells significantly decreases following CD138 sorting. CD138 sorting should not be used when studying apoptosis of myeloma cells in patient samples. Use of unsorted cells also allows for examination of the effects of interventions on other cell populations as well. When serial studies of apoptosis are done with unsorted samples, we recommend using Apo 2.7 rather than Ann/PI, since the percentage of apoptotic cells by Ann/PI expression actually appear to decrease with time in culture, thus making it difficult to assess effects of intervention such as in drug treatment studies. We hypothesize that this is due to an artificially high level of Annexin positivity at the initial study that might be brought on by non-specific damage of the membranes secondary to cell processing.
Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma.
Kumar, Shaji , Timm, Michael, Kline, Michael, Haug, Jessica, Kimlinger, Teresa K. , Yang, Dajun , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3464-3464

10.1182/blood.v108.11.3464.3464 Get It

Abstract Background: Multiple myeloma (MM) is a plasma cell proliferative disorder that results in considerable morbidity and mortality. As it is incurable with the current therapeutic approaches, more effective therapies based on better understanding of the pathobiology of the disease are needed. In MM, malignant plasma cells are characterized by low proliferative and apoptotic rates compared to other malignancies. The tumor suppressor gene p53, responsible for induction of cellular apoptosis in response to genotoxic stimuli, is relatively intact in most cases of myeloma. However, p53 mutations or deletion can occur late in the course of disease. Here we evaluate a novel small molecule inhibitor of the interaction between p53 and its negative regulator, MDM2, in the setting of myeloma. Methods and Results: Mi-63 was cytotoxic to several different myeloma cell lines with a median effect observed at approximately 2.5 μM in cell lines including MM1.S that express wild type p53 and between 10–15 μM in cells with mutated p53 as measured using an MTT cell viability assay. Additionally, Mi63 induced cytotoxicity in myeloma cell lines resistant to conventional agents such as Melphalan (LR50), Doxorubicin (Dox40) and Dexamethasone (MM1.R), indicating non-overlapping mechanisms. To evaluate the ability of the drug to induce cell death in the tumor microenvironment, MM cells were co-cultured with marrow stromal cells or in the presence of VEGF or IL-6, two cytokines known to be important for myeloma growth and survival. Mi63 was cytotoxic to myeloma cells under these conditions as well, at doses similar to those seen with myeloma cells alone. Mi63 was able to inhibit proliferation and induce apoptosis in myeloma cells in a dose- and time-dependent fashion, as demonstrated by flow cytometry using Annexin/PI staining as well as cell cycle studies. Treatment of myeloma cells with Mi63 was associated with early mitochondrial membrane depolarization, inversion of Bax/Bcl-2 ratio, and down regulation of Mcl-1, indicating induction of mitochondrial mechanisms of cell death. Mi63 was also cytotoxic to freshly isolated primary patient myeloma cells, inducing apoptosis in a dose-dependent manner. In the patient cells the drug appears to have a differential effect on the CD45 positive and negative cells. Conclusion: Mi-63 has significant activity in vitro in the setting of myeloma as demonstrated by its effect on myeloma cell lines and primary patient cells. It clearly induces apoptosis in myeloma cells, with higher activity seen in cells with wild type p53. Given the lack of p53 abnormalities in most of the patients with myeloma, this drug alone or in combination is likely to have significant clinical activity. Studies combining this with various DNA damaging drugs are in progress. These studies will eventually form the framework for future clinical studies.
High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels.
Kumar, Shaji , Katzmann, Jerry A., Kyle, Robert A. , Clark, Raynell, Fonseca, Rafaël , Dispenzieri, Angela , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3514-3514

10.1182/blood.v108.11.3514.3514 Get It

Abstract Background: An abnormal free light chain (FLC) indicating the presence of excess monoclonal FLC is associated with an increased risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) or related disorder. In addition, the risk of progression rises with increasingly abnormal FLC ratio, suggesting that the mechanism for markedly abnormal FLC ratios may be different compared to ratios closer to normal range. We hypothesized that as in light chain MM (in which IgH expression is completely lost), a more markedly abnormal FLC ratio is a marker for IgH translocations (TCs) involving 14q32. We tested this hypothesis using data obtained from gene expression profiling (GEP) to identify the presence of specific IgH TCs and correlating them to serum FLC ratio. Methods: We examined data from 128 GEPs from pts with MM (92), smoldering MM (13), MGUS (9) and primary amyloidosis (14). Presence of IgH translocations were identified using the specific probes for the partner chromosome TC sites, namely FGFR3/MMSET (4p16), cyclin D3 (6p21), cyclin D1 (11q13), c-maf (16q23), and mafB (20q12) as previously described. FLC estimation was carried out on stored serum samples from these patients using the serum FLC assay (FreeliteH, The Binding Site Limited, UK) performed on a Dade-Behring Nephelometer. Based on the established reference range, kappa/lambda FLC ratio <0.26 or >1.65 were defined as abnormal indicating the presence of monoclonal lambda and kappa FLC, respectively. The monoclonal LC isotype was considered the involved FLC isotype, and the opposite LC type as the uninvolved FLC type. Differential expression of genes was examined using Genespring 7.2 software. Results: Among the 92 pts with MM, 36 (42%) had evidence of one of the 5 primary IgH TCs: 20 pts with 11q13 (22%), 7 pts with 4p16 (8%), 4 pts with16q23 (4%), 3 pts with 20q12 (3%), and 2 patients with 6p21 (2%). Among the 11 pts with MM with an FLC ratio of > 1000, 8 (72%) had an IgH TC. The proportion of pts with an FLC ratio >1000 was significantly higher in pts with an IgH TCcompared to those without, 22% vs 5% respectively, P=0.02. The mean FLC ratio was 1728 (range; 1.6 to 31,008) in patients with an IgH TC vs. 412 (1–11340) for those without IgH TCs, P=0.09. Similarly in pts with MGUS, SMM or AL all three pts with a ratio > 50 had evidence of an IgH translocation. compared to 14/33 with lower ratio. The mean FLC ratio was 29 (range;1 to 209) in pts with an IgH TC vs. 9.1 (1–41) for those without IgH TCs, P=0.1. We correlated the results of FISH tests where available (122 of 128 pts) to determine the ability of GEP to identify IgH TCs. IgH translocation identified by the GEP could be detected on FISH in 42 of 47 patients (89%). Correspondingly, 61 of 75 patients (81%) without an IgH translocation on GEP had a similar result by FISH as well. We compared the GEP of MM pts with FLC ratio of >500 to the rest and identified 34 genes which were 2 fold differentially expressed between the two groups. Conclusion: By combining GEP data and serum FLC measurements, we show that very high FLC ratios is associated with IgH translocations. However, the correlation is not absolute, likely reflecting that markedly abnormal FLC ratios may be mediated through other mechanisms including increasing tumor load. To further explore this we analyzed differentially expressed genes between patients with high and low ratios and identified a set of 34 genes, which are currently being studied further.